Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer

New series of thiazolyl-pyrazoline derivatives (7a–7d, 10a–10d and 13a–13f) have been synthesised and assessed for their potential EGFR and VEGFR-2 inhibitory activities. Compounds 10b and 10d exerted potent and selective inhibitory activity towards the two receptor tyrosine kinases; EGFR (IC50 = 40...

Full description

Bibliographic Details
Main Authors: Esraa A. Abdelsalam, Amer Ali Abd El-Hafeez, Wagdy M. Eldehna, Mahmoud A. El Hassab, Hala Mohamed M. Marzouk, Mahmoud M. Elaasser, Nageh A. Abou Taleb, Kamilia M. Amin, Hatem A. Abdel-Aziz, Pradipta Ghosh, Sherif F. Hammad
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Anticancer
molecular docking
EGFR inhibitors
VEGFR-2 inhibitors
EGFR-mutated NSCLC
dual kinase inhibitors
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2022.2104841

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2022.2104841

Similar Items